VCBeat Health Contact Us
Home AstraZeneca and CBMG Announce $630 Million CAR-T Licensing Agreement for Global Development of C-CAR031

AstraZeneca and CBMG Announce $630 Million CAR-T Licensing Agreement for Global Development of C-CAR031

Jan 19, 2026 09:53 CST Updated 09:53
AstraZeneca

Pharmaceutical Technology Research and Development Provider

AbelZeta

Developer of Immune Cell and Stem Cell Therapy Products

Image

Opportunities to Go Global Are Here!

Looking for PCSK9 small molecule inhibitor products, interested in global rights, current stage不限.

Interested companies are invited to contact immediately: PharmaTimes BD Team
BD@drugtimes.cn

Image

Case Study on Impurity Identification and Structural Analysis in Drug Development | Porton·PharmaTimes Live Broadcast


Main Body: 610 Words
Estimated reading time: 4 minutes
On January 16, 2026, Cellular Biomedicine Group (referred to as "CBMG" or "the Company") announced an agreement with AstraZeneca, under which the latter will acquire a 50% share of CBMG's development and commercialization rights for C-CAR031 in China.AstraZeneca will obtain exclusive global rights for the development, production, and commercialization of C-CAR031.。
According to the terms of the agreement,Cellular Biomedicine Group (Shanghai) Ltd will have the right to receive up to$630 million, including the upfront payment for the GPC3 project in China as well as development, regulatory, and sales milestone payments.
AstraZeneca holds the rights to develop, manufacture, and commercialize C-CAR031 outside of China (rest of the world).For the development in other regions globally, Cellular Biomedicine Group (Shanghai) Ltd is still eligible for additional milestone payments and royalties.。
It is worth mentioning that this is not the first collaboration between the two parties. As early as December 2023, Cellular Biomedicine Group (Shanghai) Ltd. signed a joint development agreement with AstraZeneca to co-develop and commercialize in China.C-CAR031。
C-CAR031 is aAutologous, Targeted Glypican 3 (GPC3) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy, using AstraZeneca's dominant-negative transforming growth factor-β receptor II (dnTGFβRII) armored platform design, is currently under investigation for the treatment of hepatocellular carcinoma (HCC) and other solid tumors.
GPC3 is a protein that is highly expressed in HCC, renal cancer, and other cancers, while it is rarely or not expressed at all in normal tissues such as the liver. Notably, the heterogeneity and dynamic modifications of GPC3's surface glycosaminoglycan chains (e.g., heparan sulfate) form a natural barrier for drug design, making the development of related targeted drugs challenging. The frequent failures of therapies such as monoclonal antibodies and CAR-T further underscore this challenge.The Precious Development of C-CAR031.
At the 2024 ASCO Annual Meeting,Cellular Biomedicine GroupThe clinical data of C-CAR031 was published, showingThe therapyShowed preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma. The CAR031 study achieved results at all dose levels (DLs) in patients with a median follow-up of 9.03 months.91.3% Disease Control Rate (DCR) and 56.5% Objective Response Rate (ORR)In patients with DL4, the ORR was 75.0%.
References:
1.https://mp.weixin.qq.com/s/BhJat_N6j47vmmd0LB9GsA
2.Other Disclosure Information

Cover Image/Abstract Image Source: PharmaTimes

Image

2026 JPM Conference Highlights! Henlius Explains "Globalization 2.0" in Detail, Outlining Key Innovation Asset Milestones

2026-01-16

Image

Milestone for Chinese "Respiratory Drugs" Going Global! First Inhalation Powder by a Chinese Pharmaceutical Company Approved by FDA

2026-01-15

Image

Cellular Biomedicine Group (Shanghai) Ltd Selected as "2025 NVIDIA Prestigious Enterprise"

2026-01-17

Image

Facing Rumors of the "Kill Line," Trump Unveils "Great Healthcare Plan"

2026-01-17

Image


Copyright Statement/Disclaimer

This is a compiled article.

This article is for information exchange purposes only and does not provide any commercial, medical, or investment advice.

The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website/network, or used in accordance with the CC0 protocol. The copyright belongs to the respective owners, and PharmaTimes makes every effort to credit the sources.

If you have any questions, please contact us.

Sincerely grateful!

DrugTimes Official Website: www.drugtimes.cn

Contact Information:

Phone: 13651980212

WeChat: 27674131

Email: contact@drugtimes.cn

图片
ImageClickView more exciting content!